🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Recurrent Renal Cell Carcinoma

An Investigational Scan (89Zr-DFO-GmAb PET/CT) Compared to Contrast-Enhanced CT for the Detection of Recurrent Clear Cell Renal Cell Cancer After Surgery Comparing Carbonic Anhydrase IX (CAIX) PET CT to Conventional PET CT for Post-Op Staging in Kidney Cancer NCT06447103Phase 21 site📍 Los Angeles Jonsson Comprehensive Cancer Center · Tests: Biospecimen Collection, Bone Scan, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study NCT07405086Phase 41 site📍 Portland OHSU Knight Cancer Institute · Tests: Biospecimen Collection, Immune Checkpoint Inhibitor Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors NCT04777994Phase 130 sites📍 Tucson📍 New Haven📍 Baltimore Calico Life Sciences LLC · Tests: ABBV-CLS-484, Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitor (TKI), Programmed Cell Deat… CAIX PET/ CT Guided Radiation Therapy in CcRCC. NCT07540260NA1 site📍 Beijing Peking University First Hospital · Tests: PETCT-guided radiation therapy International REgistry of COnservative or Radical Treatment of Localized Kidney Tumors NCT05363657n/a37 sites📍 Los Angeles📍 San Diego📍 Stanford Azienda Ospedaliero-Universitaria Careggi · Tests: Partial Nephrectomy (PN), Radical Nephrectomy (RN), Ablation therapy (AT), Active Surveillance (AS) Contrast-Enhanced Ultrasound Imaging for Diagnosing Recurrent Renal Cell Carcinoma (RCC) Post Ablation NCT05641935Phase 21 site📍 Philadelphia john eisenbrey · Tests: Sulfur Hexafluoride Lipid Microspheres, Contrast-Enhanced Ultrasound, Computed Tomography, Magnetic Resonance Imaging, … Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid Tumors NCT07584499Phase 11 site📍 Guangzhou Sun Yat-sen University · Tests: Becotatug Vedotin Registry of Minimally Invasive Cancer Treatment Using Spectral Angio-CT Image Guidance NCT07636148n/a3 sites📍 Lyon📍 Créteil📍 Leiden Mark C Burgmans, MD PhD Study on MRD Prediction of Efficacy of Toripalimab in the Treatment of High-risk Recurrent Renal Carcinoma NCT07657325n/a1 site📍 Tianjin Tianjin Medical University Second Hospital · Tests: Toripalimab Postoperative Adjuvant Therapy for Non-clear Renal Cell Carcinoma With High-risk Recurrence Factors NCT05768464Phase 22 sites📍 Nanjing📍 Nanning The Affiliated Nanjing Drum Tower Hospital of Nanjing Unive… · Tests: Toripalimab, Axitinib A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033) NCT07227402Phase 3127 sites📍 Anchorage📍 Fullerton📍 Los Angeles Merck Sharp & Dohme LLC · Tests: Belzutifan, Zanzalintinib, Cabozantinib Contrast-enhanced CT-based Deep Learning Model for Preoperative Prediction of Disease-free Survival (DFS) in Localized Clear Cell Renal Cell Carcinoma (ccRCC) NCT06088134n/a1 site📍 Chongqing Mingzhao Xiao APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors NCT03175224Phase 235 sites📍 Los Angeles📍 Tampa📍 Boston Apollomics Inc. · Tests: APL-101 Oral Capsules SABR Combined With Targeted Therapy and Anti-PD-1 for Recurrent or Metastatic Renal Cancer NCT06583070n/a2 sites📍 Beijing📍 Beijing Peking University First Hospital · Tests: Radiation therapy, Targeted and immunotherapy 9MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial Carcinoma NCT06823427Phase 22 sites📍 Changsha📍 Nanjing Mabwell (Shanghai) Bioscience Co., Ltd. · Tests: 9MW2821, Toripalimab (JS001 ) Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03) NCT07049926Phase 1, Phase 232 sites📍 San Francisco📍 Mineola📍 New York Merck Sharp & Dohme LLC · Tests: Belzutifan, Zanzalintinib Kidney Cancer Observational Protocol NCT06147349n/a1 site📍 Milan IRCCS San Raffaele · Tests: Radical or partial nephrectomy uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto NCT05874921n/a22 sites📍 Santa Monica📍 Gainesville📍 Miami UroGen Pharma Ltd. · Tests: Jelmyto (mitomycin) for pyelocalyceal solution Phase 3 Study to Assess Safety and Efficacy of 177Lu-TLX250 in Advanced Relapsed or Recurrent ccRCC NCT07197580Phase 35 sites📍 Sydney📍 Wollongong📍 Heidelberg Telix Pharmaceuticals (Innovations) Pty Limited · Tests: 177Lu-TLX250 Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program NCT06265285Phase 21 site📍 Jacksonville Mayo Clinic · Tests: Home Health Encounter, Nivolumab, Patient Monitoring, Questionnaire Administration A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression NCT06682793Phase 1, Phase 210 sites📍 Gilbert📍 La Jolla📍 Los Angeles A2 Biotherapeutics Inc. · Tests: A2B395, xT CDx with HLA-LOH assay Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors NCT04851119Phase 1, Phase 221 sites📍 Birmingham📍 Los Angeles📍 Orange Children's Oncology Group · Tests: Biospecimen Collection, Dual X-ray Absorptiometry, Tegavivint, X-Ray Imaging Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform NCT06349642n/a3 sites📍 Phoenix📍 Jacksonville📍 Rochester Mayo Clinic · Tests: Biospecimen Collection, Tissue Collection SABR Combined with Axitinib and Toripalimab in Recurrent or Metastatic RCC NCT06889649Phase 21 site📍 Beijing Peking University First Hospital · Tests: Stereotactic Ablative Body Radiotherapy (SABR), TORIPALIMAB INJECTION(JS001 ), Axitinib (VEGF-TKI) A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors NCT06465069Phase 139 sites📍 Duarte📍 La Jolla📍 Los Angeles Eli Lilly and Company · Tests: LY4052031, Pembrolizumab Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment NCT05363280Phase 27 sites📍 Birmingham📍 Weston📍 Chicago Advenchen Pharmaceuticals, LLC. · Tests: AL8326 40 mg, AL8326 60 mg, AL8326 80 mg--stopped Clinical Trial of AM80 in Combination With Gemcitabine, Cisplatin, and Nivolumab in Patients With Urothelial Carcinoma NCT06983210Phase 21 site📍 Nagoya Nagoya University · Tests: Add-on effect of adding tamivarotene (AM80) to gemcitabine, cisplatin, and nivolumab combination therapy Irreversible Electroporation (IRE) for Treating Recurrent Pelvic Tumors (PELFIRE Study) NCT07782164n/a1 site📍 Amsterdam Amsterdam UMC, location VUmc · Tests: Irreversible electroporation Combination of Toripalimab and JS004 Therapy for ccRCC NCT06690697Phase 21 site📍 Shanghai Fudan University · Tests: JS004, Toripalimab, Axitinib, Sorafenib Patient-partnered Research in Investigating Fear of Cancer Recurrence in Kidney Cancer NCT07234656n/a3 sites📍 Aalborg📍 Aarhus📍 Herning Brigitta Rasmussen Villumsen · Tests: Phase 1: Establishment of a patient-partner panel, Phase 2: Feasibility testing of FCR questions, mode of administratio…
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy